Evaluate the Response Rate of Acute Lymphocytic Leukemia Patients to Hyper Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone Regimen and Remission Rate to Stay Until the End of the Arbitrary Treatment

Document Type : Original Article


1 Department of Hematology and Oncology, Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background: This study aimed to determine the effect of Hyper-Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone (CVAD) in the treatment of acute lymphoblastic leukemia (ALL) patients and remission duration. Materials and Methods: During a cross-sectional study in the Seyed Al-Shohada Hospital in Isfahan, patients with ALL who were admitted and treated from 2011 to 2015 because of the risk of ALL were selected and through the records investigation, demographic information, disease information, treatment, remission duration, current status, and duration of survival were collected in the form of data and are sick after going into remission, including the duration and recurrence remission survival time in treatment were analyzed and consequence, whether the patient is going into remission, remission and relapse and survival time based on the duration of treatment were analyzed. Results: Of the 62 patients, 13 patients after starting of treatment did not go to remission and died, but 49 patients (79%) went into complete remission. 21 of them of Hyper-CVAD group and 28 patients of classical treatment group (75/7% vs. 84%), but the difference was not significant (P = 0.43). Of the 48 patients who had a complete remission with the treatment regimen, ten patients relapsed after treatment with two of them of Hyper-CVAD group and eight patients were in the classical treatment group (9/5% vs. 29/6%), and the difference between the two groups was significant (P = 0.015). Conclusion: Hyper-CVAD regimen resulted in increased survival time of patients with ALL and less disease recurrence and therefore contraindications for use if the existing rules, and under the supervision of treatment, can be used.


Calvet D, Touzé E, Varenne O, Sablayrolles JL, Weber S, Mas JL. Prevalence of asymptomatic coronary artery disease in ischemic stroke patients: The PRECORIS study. Circulation 2010;121:1623-9.  Back to cited text no. 1
Esmaillzadeh A, Mirmiran P, Azizi F. Waist-to-hip ratio is a better screening measure for cardiovascular risk factors than other anthropometric indicators in Tehranian adult men. Int J Obes Relat Metab Disord 2004;28:1325-32.  Back to cited text no. 2
Rabkin SW. Epicardial fat: Properties, function and relationship to obesity. Obes Rev 2007;8:253-61.  Back to cited text no. 3
Sacks HS, Fain JN. Human epicardial adipose tissue: A review. Am Heart J 2007;153:907-17.  Back to cited text no. 4
Esmaillzadeh A, Mirmiran P, Azizi F. Comparative evaluation of anthropometric measures to predict cardiovascular risk factors in Tehranian adult women. Public Health Nutr 2006;9:61-9.  Back to cited text no. 5
Baker AR, Silva NF, Quinn DW, Harte AL, Pagano D, Bonser RS, et al. Human epicardial adipose tissue expresses a pathogenic profile of adipocytokines in patients with cardiovascular disease. Cardiovasc Diabetol 2006;5:1.  Back to cited text no. 6
Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: The Framingham Heart Study. Circulation 2008;117:605-13.  Back to cited text no. 7
Iacobellis G, Barbaro G. The double role of epicardial adipose tissue as pro- and anti-inflammatory organ. Horm Metab Res 2008;40:442-5.  Back to cited text no. 8
Iacobellis G. Imaging of visceral adipose tissue: An emerging diagnostic tool and therapeutic target. Curr Drug Targets Cardiovasc Haematol Disord 2005;5:345-53.  Back to cited text no. 9
Jeong JW, Jeong MH, Yun KH, Oh SK, Park EM, Kim YK, et al. Echocardiographic epicardial fat thickness and coronary artery disease. Circ J 2007;71:536-9.  Back to cited text no. 10
Wang CP, Hsu HL, Hung WC, Yu TH, Chen YH, Chiu CA, et al. Increased epicardial adipose tissue (EAT) volume in type 2 diabetes mellitus and association with metabolic syndrome and severity of coronary atherosclerosis. Clin Endocrinol (Oxf) 2009;70:876-82.  Back to cited text no. 11
Mustelier JV, Rego JO, González AG, Sarmiento JC, Riverón BV. Echocardiographic parameters of epicardial fat deposition and its relation to coronary artery disease. Arq Bras Cardiol 2011;97:122-9.  Back to cited text no. 12
Bettencourt N, Toschke AM, Leite D, Rocha J, Carvalho M, Sampaio F, et al. Epicardial adipose tissue is an independent predictor of coronary atherosclerotic burden. Int J Cardiol 2012;158:26-32.  Back to cited text no. 13
Yorgun H, Canpolat U, Hazirolan T, Ates AH, Sunman H, Dural M, et al. Increased epicardial fat tissue is a marker of metabolic syndrome in adult patients. Int J Cardiol 2013;165:308-13.  Back to cited text no. 14
Andrade LJ, Melo PR, Paraná R, Daltro C. Grading scale of visceral adipose tissue thickness and their relation to the nonalcoholic fatty liver disease. Arq Gastroenterol 2014;51:118-22.  Back to cited text no. 15
Gulizia R, Vercelli A, Gervasoni C, Uglietti A, Ortu M, Ferraioli G, et al. Comparability of echographic and tomographic assessments of body fat changes related to the HIV associated adipose redistribution syndrome (HARS) in antiretroviral treated patients. Ultrasound Med Biol 2008;34:1043-8.  Back to cited text no. 16
Signorini DJ, Oliveira Netto AM, Monteiro MC, Signorini DH, Codeço CT, Bastos FI, et al. Differences in body fat distribution assessed by ultrasonography in patients receiving antiretroviral drugs. Rev Assoc Med Bras 2012;58:197-203.  Back to cited text no. 17
Tsitsilonis S, Vlachos IS, Bampali A, Revenas K, Votteas V, Perrea DN. Sonographic measurements of subcutaneous fat in obese individuals may correlate better with peripheral artery disease indices. J Clin Ultrasound 2009;37:263-9.  Back to cited text no. 18
Silaghi AC, Poanta L, Valea A, Pais R, Silaghi H. Is epicardial adipose tissue, assessed by echocardiography, a reliable method for visceral adipose tissue prediction? Med Ultrason 2011;13:15-20.  Back to cited text no. 19
Bazzocchi A, Diano D, Ponti F, Salizzoni E, Albisinni U, Marchesini G, et al. A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry. Nutrition 2014;30:696-701.  Back to cited text no. 20
Gorter PM, van Lindert AS, de Vos AM, Meijs MF, van der Graaf Y, Doevendans PA, et al. Quantification of epicardial and peri-coronary fat using cardiac computed tomography; reproducibility and relation with obesity and metabolic syndrome in patients suspected of coronary artery disease. Atherosclerosis 2008;197:896-903.  Back to cited text no. 21
Rabkin SW. The relationship between epicardial fat and indices of obesity and the metabolic syndrome: A systematic review and meta-analysis. Metab Syndr Relat Disord 2014;12:31-42.  Back to cited text no. 22
Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010;28:3880-9.  Back to cited text no. 23